Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced the closing of a $32.5M Series A financing. The round was co-led by Balyasny Asset Management, venBio, and Janus Henderson In…

<ul><li>Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors</li><li>Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy for Angel…